Dr. Lal PathLabs is currently trading at Rs. 885.90, up by 7.35 points or 0.84% from its previous closing of Rs. 878.55 on the BSE.
The scrip opened at Rs. 904.00 and has touched a high and low of Rs. 904.00 and Rs. 882.30 respectively.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1134.50 on 10-Jan-2017 and a 52 week low of Rs. 717.65 on 24-Oct-2017.
Last one week high and low of the scrip stood at Rs. 904.00 and Rs. 870.00 respectively. The current market cap of the company is Rs. 7,382.00 crore.
The promoters holding in the company stood at 57.92%, while Institutions and Non-Institutions held 21.92% and 20.17% respectively.
Dr. Lal PathLabs' subsidiary -- Paliwal Diagnostics has received an approval to acquire a Proprietorship Concern. i.e. Satya Pathology and Diagnostic Centre (SPDC). The Board of Directors of the company's Subsidiary at their meeting held on December 12, 2017, approved the same.
The company's subsidiary has decided to acquire 100% stake in SPDC with the objective of strengthening its presence in market.
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.